Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Inoviq Ltd ( (AU:IIQ) ) is now available.
INOVIQ Ltd has announced a leadership transition with David Williams stepping down as Chairman, effective December 18, 2025, and Peter Gunzburg taking over the role. Gunzburg emphasized the company’s readiness to advance its well-funded product development strategy, marking a significant phase in achieving milestones to benefit patients, partners, and shareholders.
The most recent analyst rating on (AU:IIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.
More about Inoviq Ltd
INOVIQ Ltd is a leading company in the exosome technology field, focusing on advancing next-generation diagnostics and therapeutics for cancer care. Its portfolio encompasses commercial exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and preclinical CAR-exosome therapeutic programs for solid tumors, aiming to improve patient outcomes.
Average Trading Volume: 192,967
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$46.46M
For a thorough assessment of IIQ stock, go to TipRanks’ Stock Analysis page.